Fr. 79.00

McGraw Hill's 2026/2027 Top 300 Pharmacy Drug Cards

English · Cards

Will be released 06.02.2026

Description

Read more










The quickest, most efficient way to master critical facts about common drugs

Perfect for NAPLEX and course review, McGraw Hill's 2026/2027 Top 300 Pharmacy Drug Cards is the most concise and up-to-date resource for building a solid knowledge base of the most commonly used drugs. Adverse reactions are organized by common, less common, and rare but serious to help users organize thoughts for counseling patients. This updated edition includes 30 new cards.

Each card features:

- Generic and common name
- Dosage Forms
- Approved Dose and Indications
- Off-Label Use
- Contraindications
- Adverse Reactions
- Drug Interactions
- Monitoring Parameters
- Medication Safety Issues and Black Box Warnings
- Strong focus on patient safety


About the author










Jill Kolesar, PharmD, MS, BCPS, FCCP, FFIP, is professor of Pharmacy Practice and Science at UK College of Pharmacy in Lexington, KY.

Lee Vermeulen, BSPharm, MS, FCCP, is chief efficiency officer at UK HealthCare and professor of Medicine and Pharmacy at UK College of Pharmacy in Lexington, KY.

Product details

Authors Jill Kolesar, Jill M Kolesar, Lee C Vermeulen, Lee C. Vermeulen
Publisher McGraw-Hill
 
Languages English
Product format Cards
Release 06.02.2026
 
EAN 9781266067907
ISBN 978-1-266-06790-7
Illustrations Illustrationen, nicht spezifiziert
Subjects Natural sciences, medicine, IT, technology > Medicine > Clinical medicine

MEDICAL / Pharmacy, MEDICAL / Pharmacology, MEDICAL / Reference, MEDICAL / Nursing / Reference, Reference works, Pharmacology, Pharmacy / dispensing

Customer reviews

No reviews have been written for this item yet. Write the first review and be helpful to other users when they decide on a purchase.

Write a review

Thumbs up or thumbs down? Write your own review.

For messages to CeDe.ch please use the contact form.

The input fields marked * are obligatory

By submitting this form you agree to our data privacy statement.